Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 7/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10512605 | 0.83 | RAPGEF4 (0.37) | RAPGEF4NPC1RAB9AALDH1A1CNR2 | |
| SCHEMBL28133239 | 0.83 | CA1 (0.34) | CA1CA2 | |
| Hydrochloric Acid SCHEMBL30330950 | 0.81 | RAPGEF4 (0.36) | RAPGEF4NPC1RAB9AMEN1KMT2A | |
| Fluoride SCHEMBL30329730 | 0.81 | RAPGEF4 (0.36) | RAPGEF4NPC1RAB9AMEN1KMT2A | |
| SCHEMBL18979838 | 0.80 | CA1 (0.42) | CA1CA2NPC1RAB9AMEN1 | |
| SCHEMBL4127984 | 0.79 | RAPGEF4 (0.35) | RAPGEF4ALDH1A1 | |
| SCHEMBL10515132 | 0.79 | POLB (0.41) | RAPGEF4L3MBTL1NPC1RAB9AKMT2A | |
| SCHEMBL10536181 | 0.79 | RAPGEF4 (0.35) | RAPGEF4NPC1RAB9AALDH1A1CNR2 | |
| SCHEMBL11344641 | 0.79 | HTR2C (0.35) | CA1CA2ALDH1A1 | |
| SCHEMBL668145 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8558009-B2 | Pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2013-10-15 | — | — | US | disclosed |
| US-8558009-B2 | Pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2013-10-15 | — | — | US | disclosed |
| US-8558009-B2 | Pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2013-10-15 | — | — | US | disclosed |
| US-8212057-B2 | Pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2012-07-03 | — | — | US | disclosed |
| US-8212057-B2 | Pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2012-07-03 | — | — | US | disclosed |
| US-8212057-B2 | Pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2012-07-03 | — | — | US | disclosed |
| US-8110598-B2 | (+-) Ethyl 3-{4-[2-(pyrrol-1-yl)ethoxy]phenyl}-2-ethoxypropanoate; hyperlipidaemia, hypercholesteremia, hyperglycemia, obesity, impaired glucose intolerance, leptin resistance, insulin resistance, reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL or free fatty acids in the plasma | CADILA HEALTHCARE LIMITED (IN) | 2012-02-07 | — | — | US | disclosed |
| US-8110598-B2 | (+-) Ethyl 3-{4-[2-(pyrrol-1-yl)ethoxy]phenyl}-2-ethoxypropanoate; hyperlipidaemia, hypercholesteremia, hyperglycemia, obesity, impaired glucose intolerance, leptin resistance, insulin resistance, reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL or free fatty acids in the plasma | CADILA HEALTHCARE LIMITED (IN) | 2012-02-07 | — | — | US | disclosed |
| US-8110598-B2 | (+-) Ethyl 3-{4-[2-(pyrrol-1-yl)ethoxy]phenyl}-2-ethoxypropanoate; hyperlipidaemia, hypercholesteremia, hyperglycemia, obesity, impaired glucose intolerance, leptin resistance, insulin resistance, reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL or free fatty acids in the plasma | CADILA HEALTHCARE LIMITED (IN) | 2012-02-07 | — | — | US | disclosed |
| US-20110275669-A1 | Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILLA HEALTHCARE LIMITED (IN) | 2011-11-10 | — | — | US | disclosed |
| US-20070238776-A1 | Novel Pyrroles Having Hypolipidemic Hypocholesteremic Activities, Process for Their Preparation and Pharmaceutical Compositions Containing Them and Their Use in Medicine | CADILLA HEALTHCARE LIMITED (IN) | 2007-10-11 | — | — | US | disclosed |
| US-20070238776-A1 | Novel Pyrroles Having Hypolipidemic Hypocholesteremic Activities, Process for Their Preparation and Pharmaceutical Compositions Containing Them and Their Use in Medicine | CADILLA HEALTHCARE LIMITED (IN) | 2007-10-11 | — | — | US | disclosed |
| US-7179581-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-7179581-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-7041837-B2 | Heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILLA HEALTHCARE LIMITED (IN) | 2006-05-09 | — | — | US | disclosed |
| US-6987123-B2 | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2006-01-17 | — | — | US | disclosed |
| CN-1558758-A | Novel pyrrole compound with blood fat and cholesterol reducing activity, preparation method thereof, pharmaceutical composition containing same and medical application thereof | — | 2004-12-29 | — | — | CN | disclosed |
| US-20040186099-A1 | Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | LOHRAY BRAJ BHUSHAN (IN) | 2004-09-23 | — | — | US | disclosed |
| US-20030236254-A1 | Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2003-12-25 | — | — | US | disclosed |
| US-20030199498-A1 | Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199498-A1 | Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | CYP11B2, CYP11B1, MAPT | CA1 4297/4885CA2 2702/4885RAPGEF4 1481/4885 |
| US-20110275669-A1 | Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine | CETP, LIPA, LIPC | CA1 4547/4885CA2 3732/4885RAPGEF4 2691/4885 |
| US-20070238776-A1 | Novel Pyrroles Having Hypolipidemic Hypocholesteremic Activities, Process for Their Preparation and Pharmaceutical Compositions Containing Them and Their Use in Medicine | LIPC, CETP, PNLIP | CA1 4565/4885CA2 3375/4885RAPGEF4 3290/4885 |
| US-20040186099-A1 | Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | CYP11B2, CYP11B1, MAPT | CA1 4297/4885CA2 2702/4885RAPGEF4 1481/4885 |
| US-20030236254-A1 | Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine | LIPA, LIPC, CYP46A1 | CA1 4422/4885CA2 3396/4885RAPGEF4 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.